HIV-1
Clinical trials for HIV-1 explained in plain language.
Never miss a new study
Get alerted when new HIV-1 trials appear
Sign up with your email to follow new studies for HIV-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug venetoclax takes aim at HIV's secret hiding spots
Disease control Recruiting nowThis early-stage trial tests whether venetoclax, a drug used for certain blood cancers, can help eliminate the hidden HIV reservoir. The study enrolls 38 adults newly starting HIV therapy. Participants receive venetoclax in three short cycles while researchers monitor safety and …
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: Thomas Aagaard Rasmussen • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Engineered immune cells aim to keep HIV in check without daily pills
Disease control Recruiting nowThis early-phase study tests whether specially engineered immune cells (CMV-HIV CAR T cells) can help control HIV in people already on antiretroviral therapy (ART). The goal is to see if these cells can persist in the body and keep the virus suppressed, potentially allowing long-…
Matched conditions: HIV-1
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a Two-Drug HIV pill work for transgender women?
Disease control Recruiting nowThis study is testing whether switching to a two-drug HIV pill (dolutegravir plus lamivudine) can keep the virus under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pill once daily for 48 weeks. The main goal …
Matched conditions: HIV-1
Phase: PHASE4 • Sponsor: UBATEC • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
Can antibodies shield newborns from HIV? early trial begins
Prevention Recruiting nowThis early-stage study is testing whether two lab-made antibodies, PGT121.414.LS and VRC07-523LS, are safe for newborns who were exposed to HIV during birth. The 48 infants will receive one or two shots of the antibodies under the skin. Researchers will monitor for side effects a…
Matched conditions: HIV-1
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 12:39 UTC